Stay updated on Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.

Latest updates to the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page
- Check5 days agoChange DetectedThe Study Details page content appears unchanged between the two screenshots.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference2%

- Check33 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, and the Back to Top element was removed.SummaryDifference0.1%

- Check55 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

- Check62 days agoChange DetectedThe web page has been updated to include a new facility name and location, as well as specific medical topics related to colorectal cancer and various antibodies and proteins. Additionally, the version has been updated from v2.16.12 to v3.0.0.SummaryDifference2%

Stay in the know with updates to Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.